Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch
Kevin Lundquist.ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of Lytenava (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, has…
